We further explored potential correlations between PDL1 expression in LUSCC and these ratios since they have also shown prognostic significance in progression-free survival in patients affected by NSCLC with PDL1 > 50%, treated with Pembrolizumab [17]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.